Salvage surgery for cervical radioiodine refractory 18F-FDG-PET positive recurrence of papillary thyroid cancer

Purpose: Five percent of patients with differentiated thyroid cancer are diagnosed with radioiodine refractory relapse in the course of the disease. For isolated or oligometastatic cervical recurrence, resection or another local treatment is recommended. In this study, the impact of surgical treatme...

Full description

Bibliographic Details
Main Authors: C Chiapponi, H Alakus, M Faust, A M Schultheis, J Rosenbrock, M Schmidt
Format: Article
Language:English
Published: Bioscientifica 2021-09-01
Series:Endocrine Connections
Subjects:
Online Access:https://ec.bioscientifica.com/view/journals/ec/10/9/EC-21-0232.xml
id doaj-9ed89c272a7e457894a1549783f1af0c
record_format Article
spelling doaj-9ed89c272a7e457894a1549783f1af0c2021-09-23T10:08:20ZengBioscientificaEndocrine Connections2049-36142021-09-0110911801188https://doi.org/10.1530/EC-21-0232Salvage surgery for cervical radioiodine refractory 18F-FDG-PET positive recurrence of papillary thyroid cancerC Chiapponi0H Alakus1M Faust2A M Schultheis3J Rosenbrock4M Schmidt5Department of General, Visceral, Cancer and Transplant Surgery, University Hospital of Cologne, Cologne, GermanyDepartment of General, Visceral, Cancer and Transplant Surgery, University Hospital of Cologne, Cologne, GermanyPolyclinic for Endocrinology, Diabetes and Preventive Medicine, University Hospital of Cologne, Cologne, GermanyDepartment of Pathology, University Hospital of Cologne, Cologne, GermanyDepartment of Radiation Therapy, University Hospital of Cologne, Cologne, GermanyDepartment of Nuclear Medicine, Faculty of Medicine, University Hospital of Cologne, Cologne, GermanyPurpose: Five percent of patients with differentiated thyroid cancer are diagnosed with radioiodine refractory relapse in the course of the disease. For isolated or oligometastatic cervical recurrence, resection or another local treatment is recommended. In this study, the impact of surgical treatment of cervical radioiodine refractory 18F-FDG-PET positive relapse of papillary thyroid cancer (PTC) was evaluated. Methods: Patients receiving radioiodine therapy between 2005 and 2015 at the University Hospital of Cologne, Germany, for PTC were screened. The subgroup of patients undergoing surgery during the course of disease after recommendation by a multidisciplinary endocrine team for cervical radioiodine refractory 18F-FDG-PET positive recurrence was identified. Demographics, clinic-pathologic characteristics, oncologic treatment, and outcome were analyzed. Results: Thirty (3%) of 969 patients with PTC treated with radioiodine therapy at our institution underwent surgery for radioiodine refractory 18F-FDG-PET positive cervical recurrence during the course of the disease. In eight (26.6%) patients, more than one operation was performed. Sixteen (53%) patients received external beam radiation therapy (EBRT) after surgery. Follow-up was on average, 79.2 ± 61.6 months after the last surgical treatment. Biochemical and radiological cure was seen in 12 (40%) patients. Remission was significantly more frequent in younger patients (P = 0.0001) with lymph node rather than soft tissue tumor recurrence (P = 0.004). Conclusions: Surgical treatment of radioiodine refractory 18F-FDG-PET positive cervical recurrence led to biochemical and radiological cure in about 40% of patients in this study. Further data are needed concerning risk stratification of potent ial subgroups benefitting of surgical approach and the possible role of EBRT after repetitive surgery. https://ec.bioscientifica.com/view/journals/ec/10/9/EC-21-0232.xmlradioiodine refractory diseasesalvage surgeryexternal beam radiotherapy
collection DOAJ
language English
format Article
sources DOAJ
author C Chiapponi
H Alakus
M Faust
A M Schultheis
J Rosenbrock
M Schmidt
spellingShingle C Chiapponi
H Alakus
M Faust
A M Schultheis
J Rosenbrock
M Schmidt
Salvage surgery for cervical radioiodine refractory 18F-FDG-PET positive recurrence of papillary thyroid cancer
Endocrine Connections
radioiodine refractory disease
salvage surgery
external beam radiotherapy
author_facet C Chiapponi
H Alakus
M Faust
A M Schultheis
J Rosenbrock
M Schmidt
author_sort C Chiapponi
title Salvage surgery for cervical radioiodine refractory 18F-FDG-PET positive recurrence of papillary thyroid cancer
title_short Salvage surgery for cervical radioiodine refractory 18F-FDG-PET positive recurrence of papillary thyroid cancer
title_full Salvage surgery for cervical radioiodine refractory 18F-FDG-PET positive recurrence of papillary thyroid cancer
title_fullStr Salvage surgery for cervical radioiodine refractory 18F-FDG-PET positive recurrence of papillary thyroid cancer
title_full_unstemmed Salvage surgery for cervical radioiodine refractory 18F-FDG-PET positive recurrence of papillary thyroid cancer
title_sort salvage surgery for cervical radioiodine refractory 18f-fdg-pet positive recurrence of papillary thyroid cancer
publisher Bioscientifica
series Endocrine Connections
issn 2049-3614
publishDate 2021-09-01
description Purpose: Five percent of patients with differentiated thyroid cancer are diagnosed with radioiodine refractory relapse in the course of the disease. For isolated or oligometastatic cervical recurrence, resection or another local treatment is recommended. In this study, the impact of surgical treatment of cervical radioiodine refractory 18F-FDG-PET positive relapse of papillary thyroid cancer (PTC) was evaluated. Methods: Patients receiving radioiodine therapy between 2005 and 2015 at the University Hospital of Cologne, Germany, for PTC were screened. The subgroup of patients undergoing surgery during the course of disease after recommendation by a multidisciplinary endocrine team for cervical radioiodine refractory 18F-FDG-PET positive recurrence was identified. Demographics, clinic-pathologic characteristics, oncologic treatment, and outcome were analyzed. Results: Thirty (3%) of 969 patients with PTC treated with radioiodine therapy at our institution underwent surgery for radioiodine refractory 18F-FDG-PET positive cervical recurrence during the course of the disease. In eight (26.6%) patients, more than one operation was performed. Sixteen (53%) patients received external beam radiation therapy (EBRT) after surgery. Follow-up was on average, 79.2 ± 61.6 months after the last surgical treatment. Biochemical and radiological cure was seen in 12 (40%) patients. Remission was significantly more frequent in younger patients (P = 0.0001) with lymph node rather than soft tissue tumor recurrence (P = 0.004). Conclusions: Surgical treatment of radioiodine refractory 18F-FDG-PET positive cervical recurrence led to biochemical and radiological cure in about 40% of patients in this study. Further data are needed concerning risk stratification of potent ial subgroups benefitting of surgical approach and the possible role of EBRT after repetitive surgery.
topic radioiodine refractory disease
salvage surgery
external beam radiotherapy
url https://ec.bioscientifica.com/view/journals/ec/10/9/EC-21-0232.xml
work_keys_str_mv AT cchiapponi salvagesurgeryforcervicalradioiodinerefractory18ffdgpetpositiverecurrenceofpapillarythyroidcancer
AT halakus salvagesurgeryforcervicalradioiodinerefractory18ffdgpetpositiverecurrenceofpapillarythyroidcancer
AT mfaust salvagesurgeryforcervicalradioiodinerefractory18ffdgpetpositiverecurrenceofpapillarythyroidcancer
AT amschultheis salvagesurgeryforcervicalradioiodinerefractory18ffdgpetpositiverecurrenceofpapillarythyroidcancer
AT jrosenbrock salvagesurgeryforcervicalradioiodinerefractory18ffdgpetpositiverecurrenceofpapillarythyroidcancer
AT mschmidt salvagesurgeryforcervicalradioiodinerefractory18ffdgpetpositiverecurrenceofpapillarythyroidcancer
_version_ 1717370545227431936